AIMT News and Press, Aimmune Therapeutics Inc. From 07/30/20

PALFORZIA ® launch gaining momentum as allergist offices begin to re-open EU and Swiss regulatory reviews for PALFORZIA remain on schedule Enrollment in phase 3 POSEIDON trial has resumed    $318 million cash, cash equivalents and investments Cost c...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, July 30, 2020, at 4:30 p.m. ET to discuss its financial results fo...

-- Peanut-Allergic Patients Treated with PALFORZIA Showed Desensitization to Peanut Protein with a Predictable Safety Profile at Nine Months – --Clinically Meaningful Improvements in Food Allergy Quality of Life Were Reported in all Age Groups -- Aimmune Therapeutics, Inc. ...

For Wall Street and retail investors, this has been a challenging year like none before it. Whether you're a novice investor or someone who's seen their fair share of recessions, there's simply nothing that could have prepared folks for the disruption caused by the coronavirus disease 2019 (COVI...

The second half of the year could provide some solid wins for investors in the cancer therapeutics market. In recent years, Wall Street has flocked to many of these biotechnology companies because of their potential to deliver cutting-edge treatments and generate long-term returns. As cancer ...

— Proven Biopharmaceutical Leader Brings Deep, Global Experience with Technical Development, Manufacturing and Supply Chain Operations — Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-t...

DBV Technologies (NASDAQ: DBVT) , a biopharmaceutical company based in France, provided a business update today regarding Viaskin, a potential peanut allergy treatment the company developed that is currently being reviewed by the U.S. Food and Drug Administration (FDA). DBV Technologies expre...

Aimmune Therapeutics (NASDAQ: AIMT) has performed significantly worse than the broader market of late. The company's stock fell by more than 50% during the first quarter of the year, and even though it has rebounded somewhat, Aimmune's shares are still down by 43% year to date. If Aimmune ca...

BioCryst Pharmaceuticals Goes Ahead with Expanded Access Program for Berotralstat BioCryst Pharmaceuticals Inc. ( BCRX ) announced launching its Expanded Access Program for berotralstat. The program will allow physicians to request the drug for hereditary angioedema patients who do not h...

Aimmune Therapeutics ( AIMT +3.6% ) announces positive data from a follow-on study to its Phase 3 PALISADE trial of peanut allergy product Palforzia [peanut (Arachis hypogaea) allergen powder-dnfp]. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Stocks on the mov...